ERBB2 and triple-negative breast carcinoma: In this review, we will discuss the most novel breast cancer treatments for HER2-positive, HER2-negative, and triple-negative breast cancers, and the possibilities implicated in combinatorial therapy for the future of breast cancer medicine (Table 1).